Taking place in Tokyo, Japan, the 3rd CoBrCa runs from today until Saturday.
Patients with primary hyperoxaluria experience kidney stones from a young age and can develop progressive oxalate nephropathy. Progression to kidney failure often develops over a number of years, and is associated with systemic oxalosis, intensive dialysis, and often combined kidney and liver transplantation.
Calliditas Therapeutics announced the submission of a New Drug Application (NDA) to the FDA for Nefecon (budesonide), a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN).
A long-term follow-up to a major study of finasteride, from Merck, confirms that the drug has no impact on lifespan...
Aspire Bariatrics announced that the results of the PATHWAY study of AspireAssist, a 171-subject, multicenter randomized control trial in the...
The duration of protection in children and adults resulting from hepatitis B vaccination is unknown.
Objective: To review efficacy and safety of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide for type 2 diabetes (T2D).
Horizon Therapeutics plc announced that the FDA has approved the supplemental Biologics License Application (sBLA) expanding the labeling to include Krystexxa, (pegloticase) injection co-administered with methotrexate, which will help more people with uncontrolled gout achieve a complete response to therapy.
Cidara Therapeutics announced the peer-reviewed publication of data from the completed pivotal ReSTORE Phase III clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential treatment for candidemia and invasive candidiasis
Cidara Therapeutics, Inc. and Mundipharma announced positive topline data from the pivotal ReSTORE Phase III clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis